Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of AVP-923 in the Treatment of Levodopa-induced Dyskinesia in Parkinson's Disease Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Males and females 30 to 80 years of age, inclusive.~* Diagnosis of idiopathic PD meeting the United Kingdom Parkinson's disease Society Brain Bank criteria.~* Levodopa-induced dyskinesia present greater than 25% of the day as per MDS-UPDRS.~* Dyskinesia of at least moderate severity as per MDS-UPDRS~* Amantadine and Monoamine Oxidase (MAO) inhibitors must be discontinued at least three weeks prior to randomization.~* Subjects currently receiving anti-parkinsonian medications, including all Levodopa preparations are eligible provided they have been on a stable dose of these medications for at least 1 month prior to randomization.~* Concomitant use of antidepressants such as selective serotonin reuptake inhibitors are allowed, provided the dose has been stable for at least 1 month prior to randomization.~Exclusion Criteria:~* Subject had a prior surgery for PD except Deep Brain Stimulation (Deep Brain Stimulation must not have been performed within one year of screening)~* Hoehn and Yahr score of 5 when off.~* Subject with Cognitive impairment and/or history of psychiatric manifestations or active hallucinations.~* Subjects with any history of complete heart block, QTc prolongation, or torsades de pointes.~* Subjects with any family history of congenital QT interval prolongation syndrome.~* Subjects with history of postural syncope, or any history of unexplained syncope within the last 12 months.~* Subjects with a history of substance and/or alcohol abuse within the past 2 years.

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- AVP-923-45 (Type: EXPERIMENTAL): AVP-923-45 twice daily for 14 days
- Placebo (Type: PLACEBO_COMPARATOR): Placebo twice a day for 14 days

Based on this trial design, predict the completion outcome and termination type (if applicable).